Synovial fibroblasts: Key players in rheumatoid arthritis

Rheumatology

Volumn 45, Issue 6, 2006, Pages 669-675

  Huber, Lars C ^a   Distler, O ^a   Tarner, I ^b   Gay, R E ^a   Gay, S ^a   Pap, T ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYCLOPHOSPHAMIDE; CYTOKINE; INTERLEUKIN 6 ANTIBODY; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METHOTREXATE; RITUXIMAB; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL CYCLE; CELL STRUCTURE; CELL TYPE; CHRONIC DISEASE; CLINICAL TRIAL; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; JOINT DESTRUCTION; MACROPHAGE; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; SYNOVIUM; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL CYCLE; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; SYNOVIAL MEMBRANE; TRANSCRIPTION FACTORS;

EID: 33745612984     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel065     Document Type: Review

References (100)

1. Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med 2001;345:1331-5.
2. Ermann J, Fathman CG. Autoimmune diseases: Genes, bugs and failed regulation. Nat Immunol 2001;2:759-61.
3. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: Why and where it occurs. Nat Med 2001;7:899-905.
4. Smith JB, Haynes MK. Rheumatoid arthritis-a molecular understanding. Ann Intern Med 2002;136:908-22.
5. Silman AJ. Epidemiology and Genetics of Rheumatoid Arthritis. Arthritis Res 2002;4(Suppl 3):S265-272.
6. Tarner IH, Fathman CG. Gene therapy in autoimmune disease. Curr Opin Immunol 2001;13:676-82.
7. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
8. Feldmann M, Maini RN. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 1999;38(Suppl 2):3-7.
9. Tarner IH, Muller-Ladner U, Gay RE, Fathman CG, Gay S. The Pathogenesis of Rheumatoid Arthritis - Gene Transfer to Detect Novel Targets for Treatment. Frontiers in Autoimmunity 2003;IOS Press, Amsterdam:315-346.
10. Muller-Ladner U, Kriegsmann J, Franklin BN, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996;149:1607-15.
11. Geiler T, Kriegsmann J, Keyszer GM, Gay RE, Gay S. A new model for rheumatoid arthritis generated by engraftment of rheumatoid synovial tissue and normal human cartilage into SCID mice. Arthritis Rheum 1994;37:1664-71.
12. Nakano K, Okada Y, Saito K, Tanaka Y. Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis Rheum 2004;50:2450-8.
13. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002;61(Suppl 2):iI84-6.
14. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-69.
15. Fassbender HG. Histomorphological basis of articular cartilage destruction in rheumatoid arthritis. Coll Relat Res 1983;3:141-55.
16. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 1989;83:1267-76.
17. Brentano F, Kyburz D, Schorr O, Gay R, Gay S. The role of Toll-like receptor signalling in the pathogenesis of arthritis. Cell Immunol 2005;233:90-6.
18. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005;52:2656-65.
19. Pierer M, Rethage J, Seibl R, et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004;172:1256-65.
20. Jungel A, Distler JH, Kurowska-Stolarska M, et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1468-76.
21. Ikeuchi H, Kuroiwa T, Hiramatsu N, et al. Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum 2005;52:1037-46.
22. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. Embo J 1991;10:4025-31.
23. Zwerina J, Hayer S, Tohidast-Akrad M, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50:277-90.
24. Muller-Ladner U, Pap T, Gay RE, Gay S. Gene transfer as a future therapy for rheumatoid arthritis. Expert Opin Biol Ther 2003;3:587-98.
25. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med 2002;6:357-76.
26. Muller-Ladner U, Kriegsmann J, Tschopp J, Gay RE, Gay S. Demonstration of granzyme A and perforin messenger RNA in the synovium of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:477-84.
27. Distler JH, Jungel A, Huber LC, et al. The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA 2005;102:2892-7.
28. Berckmans RJ, Nieuwland R, Tak PP, et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 2002;46:2857-66.
29. Rinaldi N, Schwarz-Eywill M, Weis D, et al. Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins. Ann Rheum Dis 1997;56:45-51.
30. Ishikawa H, Hirata S, Andoh Y, et al. An immunohistochemical and immunoelectron microscopic study of adhesion molecules in synovial pannus formation in rheumatoid arthritis. Rheumatol Int 1996;16:53-60.
31. Kriegsmann J, Keyszer GM, Geiler T, Brauer R, Gay RE, Gay S. Expression of vascular cell adhesion molecule-1 mRNA and protein in rheumatoid synovium demonstrated by in situ hybridization and immunohistochemistry. Lab Invest 1995;72:209-14.
32. Schwartz MA. Integrins, oncogenes, and anchorage independence. J Cell Biol 1997;139:575-8.
33. Neidhart M, Zaucke F, von Knoch R, et al. Galectin-3 is induced in rheumatoid arthritis synovial fibroblasts after adhesion to cartilage oligomeric matrix protein. Ann Rheum Dis 2005;64:419-24.
34. Trabandt A, Aicher WK, Gay RE, et al. Expression of the collagenolytic and Ras-induced cysteine proteinase cathepsin L and proliferation-associated oncogenes in synovial cells of MRL/I mice and patients with rheumatoid arthritis. Matrix 1990;10:349-61.
35. Trabandt A, Aicher WK, Gay RE, Sukhatme VP, Fassbender HG, Gay S. Spontaneous expression of immediately-early response genes c-fos and egr-1 in collagenase-producing rheumatoid synovial fibroblasts. Rheumatol Int 1992;12:53-9.
36. Dooley S, Herlitzka I, Hanselmann R, et al. Constitutive expression of c-fos and c-jun, overexpression of ets-2, and reduced expression of metastasis suppressor gene nm23-H1 in rheumatoid arthritis. Ann Rheum Dis 1996;55:298-304.
37. Grimbacher B, Aicher WK, Peter HH, Eibel H. Measurement of transcription factor c-fos and EGR-1 mRNA transcription levels in synovial tissue by quantitative RT-PCR. Rheumatol Int 1997;17:109-12.
38. Kontny E, Ziolkowska M, Dudzinka E, Filipowicz-Sosnowska A, Ryzewska A. Modified expression of c-Fos and c-Jun proteins and production of interleukin-1 beta in patients with rheumatoid arthritis. Clin Exp Rheumatol 1995;13:51-7.
39. Asahara H, Fujisawa K, Kobata T, et al. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum 1997;40:912-8.
40. Qu Z, Garcia CH, O'Rourke LM, Planck SR, Kohli M, Rosenbaum JT. Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. Arthritis Rheum 1994;37:212-20.
41. Dike LE, Farmer SR. Cell adhesion induces expression of growth-associated genes in suspension-arrested fibroblasts. Proc Natl Acad Sci USA 1988;85:6792-6.
42. Pap T, Gay S, Schett G. Matrix Metalloproteinases. In: Smolen J, Lipsky J, Dunitz M, eds. Targeted therapies in rheumatology. 2002:483-497.
43. Trabandt A, Gay RE, Fassbender HG, Gay S. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum 1991;34:1444-51.
44. van der Laan WH, Pap T, Ronday HK, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor. Arthritis Rheum 2000;43:1710-8.
45. Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: What is all the fuss about? Matrix Biol 1997;15:519-26.
46. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: Differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000;43:801-11.
47. Barchowsky A, Frleta D, Vincenti MP. Integration of the NF-kappaB and mitogen-activated protein kinase/AP-1 pathways at the collagenase-1 promoter: Divergence of IL-1 and TNF-dependent signal transduction in rabbit primary synovial fibroblasts. Cytokine 2000;12:1469-79.
48. Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 2001;166:3491-8.
49. Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000;43:2501-12.
50. Gum R, Juarez J, Allgayer H, Mazar A, Wang Y, Boyd D. Stimulation of urokinase-type plasminogen activator receptor expression by PMA requires JNK1-dependent and -independent signaling modules. Oncogene 1998;17:213-25.
51. Korzus E, Nagase H, Rydell R, Travis J. The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem 1997;272:1188-96.
52. Pap T, Nawrath M, Heinrich J, et al. Cooperation of Ras- and c-Mycdependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2004;50:2794-802.
53. Keyszer GM, Heer AH, Kriegsmann J, et al. Comparative analysis of cathepsin L, cathepsin D, and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by in situ hybridization. Arthritis Rheum 1995;38:976-84.
54. Schedel J, Seemayer CA, Pap T, et al. Targeting cathepsin L (CL) by specfic ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Ther 2004;11:1040-1047.
55. Hummel KM, Petrow PK, Franz JK, et al. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction. J Rheumatol 1998;25:1887-94.
56. Guinec N, Dalet-Fumeron V, Pagano M. "In vitro" study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. Biol Chem Hoppe Seyler 1993;374:1135-46.
57. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 1992;52:3610-4.
58. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, Terao T. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1993;1178:55-62.
59. Lakka SS, Gondi CS, Yanamandra N, et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004;23:4681-9.
60. Lemaire R, Huet G, Zerimech F, et al. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br J Rheumatol 1997;36:735-43.
61. Huet G, Flipo RM, Colin C, et al. Stimulation of the secretion of latent cysteine proteinase activity by tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1993;36:772-80.
62. Collette J, Ulku AS, Der CJ, Jones A, Erickson AH. Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int J Cancer 2004;112:190-9.
63. Mishiro T, Nakano S, Takahara S, et al. Relationship between cathepsin B and thrombin in rheumatoid arthritis. J Rheumatol 2004;31:1265-73.
64. Franz JK, Pap T, Hummel KM, et al. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum 2000;43:599-607.
65. Perlman H, Liu H, Georganas C, et al. Differential expression pattern of the antiapoptotic proteins, Bcl-2 and FLIP, in experimental arthritis. Arthritis Rheum 2001;44:2899-908.
66. Schedel J, Gay RE, Kuenzler P, et al. FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis Rheum 2002;46:1512-8.
67. Catrina AI, Ulfgren AK, Lindblad S, Grondal L, Klareskog L. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 2002;61:934-6.
68. Goberdhan DC, Wilson C. PTEN: Tumour suppressor, multifunctional growth regulator and more. Hum Mol Genet 2003;12 Spec No 2:R239-48.
69. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. Activation of synovial fibroblasts in rheumatoid arthritis: Lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res 2000;2:59-64.
70. Seemayer CA, Kuchen S, Neidhart M, et al. p53 in rheumatoid arthritis synovial fibroblasts at sites of invasion. Ann Rheum Dis 2003;62:1139-44.
71. Kuchen S, Seemayer CA, Kuenzler P, et al. Cytokine-Independent up-Regulation of Matrix Metalloproteinase 1 mRNA Expression by the Stress Activated Protein Kinase 4. Arthritis and Rheum. 2001;44:S183.
72. Ospelt C, Neidhart M, Michel BA, Simmen B, Gay RE, Gay S. p38delta induces MMP-3 in activated rhuematoid arthritis synovial fibroblasts. Arthritis and Rheumatism 2004;50:S155.
73. Suzuki M, Tetsuka T, Yoshida S, et al. The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-alpha- or IL-1beta-stimulated rheumatoid synovial fibroblasts. FEBS Lett 2000;465:23-7.
74. Neidhart M, Rethage J, Kuchen S, et al. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: Association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum 2000;43:2634-47.
75. Miagkov AV, Kovalenko DV, Brown CE, et al. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998;95:13859-64.
76. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91.
77. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998;95:15671-6.
78. Abraham E, Gyetko MR, Kuhn K, et al. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003;170:5644-51.
79. Hasegawa T, Sorensen L, Dohi M, Rao NV, Hoidal JR, Marshall BC. Induction of urokinase-type plasminogen activator receptor by IL-1 beta. Am J Respir Cell Mol Biol 1997;16:683-92.
80. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22.
81. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 2004;24:1007-21.
82. Aupperle K, Bennett B, Han Z, Boyle D, Manning A, Firestein G. NF-kappa B regulation by I kappa B kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 2001;166:2705-11.
83. Gustin JA, Ozes ON, Akca H, et al. Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidy-linositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem 2004;279:1615-20.
84. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction? Ann Rheum Dis 1993;52(Suppl 1):S39-47.
85. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
86. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-50.
87. Baslund B, Tvede N, Danneskiold-Samsoe B, Peterson J, Peterson L, Schuurmann J. A novel human monoclonal antibody against IL-15 (humax-IL-15) in patients with active rheumatoid arthritis (RA): Results of a double-blind, placebo-controlled phase I/II trial. Arthritis Rheum 2003;48:S653.
88. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002;46:802-5.
89. Plater-Zyberk C, Joosten LA, Helsen MM, et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001;108:1825-32.
90. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
91. Cheson BD. CHOP plus rituximab-balancing facts and opinion. N Engl J Med 2002;346:280-2.
92. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
93. Huber LC, Pap T, Muller-Ladner U, Gay RE, Gay S. Gene targeting: Roadmap to future therapies. Curr Rheumatol Rep 2004;6:323-5.
94. Braun T, Carvalho G, Coquelle A, et al. NF-{kappa}B constitutes a potential therapeutic target in high-risk myelodysplastic syndromes. Blood 2006;107:1156-65.
95. Tak PP, Gerlag DM, Aupperle KR, et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001;44:1897-907.
96. Nonomura Y, Kohsaka H, Nasu K, Terada Y, Ikeda M, Miyasaka N. Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21(Cip1) gene into the joints. Int Immunol 2001;13:723-31.
97. Wakisaka S, Suzuki N, Saito N, Ochi T, Sakane T. Possible correction of abnormal rheumatoid arthritis synovial cell function by jun D transfection in vitro. Arthritis Rheum 1998;41:470-81.
98. Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004;6:96-102.
99. Rutkauskaite E, Zacharias W, Schedel J, et al. Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2004;50:1448-56.
100. van der Laan WH, Quax PH, Seemayer CA, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther 2003;10:234-42.